June 8, 2024

Six years of hard work and fruitful results

Six years is the length of a historical mark.

It records GeneCradle's pace of development, progress and steady growth.

It measures GeneCradle's efforts to keep pace with the times, accumulate energy, and innovate and develop.

GeneCradle is embarking on a new journey, based on needs and benefiting patients.

Six years of craftsmanship to build dreams

GeneCradle is growing in the sun and has great potential for development

Six years of hard work

GeneCradle is renewed by light and imbued with powerful influence

GeneCradle people are striving for excellence in a down-to-earth manner

GeneCradle people strive for breakthroughs in their enterprising spirit

There is nothing trivial about making medicine. Using medicine is like using soldiers.

All GeneCradle people
will continue to promote gene medicine
from basic research to clinical and market as our mission
and are committed to exploring gene therapy
to find more solutions to disease problems
for the benefit of human health!

About GeneCradle

Beijing GeneCradle Technology Co., Ltd. is a national high-tech enterprise with the development of gene therapy drugs mediated by AAV vector delivery technology as its core business. Its mission is to promote China's rare disease gene drugs from basic to clinical and market, benefiting patients and families. The company focuses on the development of gene therapy drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases and ophthalmic diseases. By promoting the development and clinical application of rare disease gene drugs, it has a deeper understanding of life and health, and has transitioned gene therapy technologies and products from rare diseases to the treatment and rehabilitation of chronic diseases and other major diseases.